Erica Mencarelli

Erica Mencarelli

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RARachele Adorisio
Rachele Adorisio
EMErica Mencarelli
Erica Mencarelli
NCNicoletta Cantarutti
Nicoletta Cantarutti
CCCamilla Calvieri
Camilla Calvieri
LALiliana Amato
Liliana Amato
AAAntonio Amodeo
Antonio Amodeo
Duchenne muscular dystrophy (DMD) cardiomyopathy (DCM) is characterized by a hypokinetic, dilated phenotype progressively increasing with age. Regular cardiac care is crucial in DMD care. Early recognition and prophylactic use of angiotensin converting enzyme inhibitors (ACEi) are the main stay therapeutic strategy to delay incidence of DMD-DCM. Pharmacological treatment to improve symptoms and left ventricle (LV) systolic function, have been widely implemented in the past years. Because of lack of DMD specific drugs, actual indications for established DCM include current treatment for heart failure (HF). This review focuses on current HF strategies to identify, characterize, and treat DMD-DCM.

11 September 2019 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
AVAngelo Villano
Angelo Villano
EMErica Mencarelli
Erica Mencarelli
VMVeronica Melita
Veronica Melita
ARAlessandro Rizzi
Alessandro Rizzi
PLPriscilla Lamendola
Priscilla Lamendola
FCFilippo Crea
Filippo Crea

Verified
Journal Article
Open access
PDF file
EPEnrico Piccinelli
Enrico Piccinelli
GGGiorgia Grutter
Giorgia Grutter
MPMara Pilati
Mara Pilati
MRMicol Rebonato
Micol Rebonato
SSSilvia Teresa Scalera
Silvia Teresa Scalera
Gianfranco ButeraGianfranco Butera
Gianfranco Butera
The CardioMEMS HF System (Abbott, Abbott Park, IL) is the first FDA- and CE-Mark-approved device for monitoring patients with heart failure, significantly reducing hospitalizations and improving the quality of life for NYHA class III non-congenital adult patients. This device, implanted percutaneously, allows the direct monitoring of pulmonary arterial pressure with the wireless transfer of pressure data to the clinician, who can adjust the therapy remotely. Limited experience exists regarding its use in patients with congenital heart disease (CHD). CardioMEMS device implantation is feasible and safe in selected adults and children with CHD. The potential of the device to reduce heart failure hospitalizations in this population is enormous, but further multi-center studies are needed to demonstrate its efficacy.

9 September 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GLGaetano Antonio Lanza
Gaetano Antonio Lanza
EMErica Mencarelli
Erica Mencarelli
VMVeronica Melita
Veronica Melita
ATAntonio Tota
Antonio Tota
MGMaurizio Gabrielli
Maurizio Gabrielli
FFFrancesco Franceschi
Francesco Franceschi
Previous studies showed that troponin blood levels may increase after exercise. In this study we assessed whether, among patients admitted with suspected unstable angina, the increase in high-sensitive troponin T (hs-TnT) levels after exercise stress test (EST) might help identify those with obstructive coronary artery disease (CAD) and predict symptom recurrence during short term follow-up. Maximal treadmill EST was performed in 69 consecutive patients admitted to the emergency room with a suspicion of unstable angina (acute chest pain but confirmed normal serum levels of cardiac troponins) was measured before and 4 hours after EST. Coronary angiography was performed in 22 patients (32.8%). hs-TnT increased after EST compared to baseline in the whole population (from 0.84±0.65 to 1.17±0.87 ng/dL, p<0.001). The increase was similar in patients with positive (n = 14) and negative (n = 55) EST (p = 0.72), and was also similar in patients with (n = 12) and without (n = 10) obstructive CAD at angiography (p = 0.91). The achievement of a heart rate at peak EST ≥85% of that predicted for age was the variable mainly associated with the post-EST hs-TnT increase at multivariable linear regression analysis (p = 0.005). The change after EST of hs-TnT did not predict the recurrence of symptoms or readmission for chest pain at 6-month follow-up. Our data show that hs-TnT increased after EST in patients with suspected unstable angina, which seemed largely independent of most clinical and laboratory variables. Thus, hs-TnT assessed after EST does not seem to be helpful to identify patients with obstructive CAD in this kind of patients.

1 October 2018
Verified
Journal Article
Closed access
Michele GolinoMichele Golino
Michele Golino
FSF. R. Spera
F. R. Spera
LML. Manfredonia
L. Manfredonia
AVA. De Vita
A. De Vita
AFA. Di Franco
A. Di Franco
FCF. Crea
F. Crea

1 April 2019 in Journal of Cardiovascular Medicine
Verified
Journal Article
Closed access
GLGaetano Antonio Lanza
Gaetano Antonio Lanza
VMVeronica Melita
Veronica Melita
EMErica Mencarelli
Erica Mencarelli
AVAntonio De Vita
Antonio De Vita
ABAntonio Bisignani
Antonio Bisignani
FCFilippo Crea
Filippo Crea
Background: Although some previous studies assessed characteristics and outcome of patients with suspected no-ST-segment elevation acute myocardial infarction (NSTEMI), but no obstructive coronary artery disease (NOCAD) at angiography, most were performed before high-sensitivity troponin assays were available. Methods and results: We reviewed data of patients admitted to our hospital with a suspicion of NSTEMI between 2013 and 2016. Patients with previous evidence of CAD (except those with fully percutaneous coronary revascularization) were excluded. Patients were divided into those with obstructive CAD and those with NOCAD (no coronary stenosis ≥50% in any vessel). The final population included 430 patients – 317 (73.7%) with CAD and 113 (26.3%) with NOCAD. Compared with CAD, NOCAD patients were younger, more frequently women, and had a lower prevalence of cardiovascular risk factors and peak troponin level. In-hospital death or myocardial infarction occurred in eight (2.5%) and two (1.8%) patients in CAD and NOCAD patients, respectively (P = 1.00). A lower left ventricular ejection fraction (LVEF) and left main CAD were the only independent predictors of in-hospital death and death or myocardial infarction. Conclusions: Among patients with suspect NSTEMI, about one-fourth showed NOCAD at angiography in the era of elevated sensitivity troponin assays and when excluding patients with largely predictable obstructive CAD. Higher troponin levels were associated with obstructive CAD, but a lower LVEF and left main disease only predicted in-hospital outcome in this population.